The SHINE trial, which studied the small molecular FGFR1/2/3 inhibitor AZD4547 versus paclitaxel in advanced gastric cancer with FGFR2 polysomy or gene amplification, did not show any statistically significant difference in PFS in favor of the AZD4547 arm compared with paclitaxel. The gene discussed is FGFR2; the disease is gastric cancer.